THE EXECUTIVE SUMMARY

HEALING WOUNDS. IMPROVING LIVES

Management Team

Chief Executive Officer
Waleed Abdel-Naby, Ph.D.
Co-inventor and Entrepreneur
Author of several scientific publications and patent applications.. Management experience at SilkTears Inc.

Chief Scientific Officer
Ryan Schreiner, Ph.D.
Tech Development Extraordinaire
Exceptional Scientist with experience in development of novel therapeutics for regenerative medicine and biomedical applications

Scientific Advisor
Enrique Rodriguez-Boulan, M.D.
Charles and Margaret Dyson Professor in Cell and Developmental Biology
He has extensive experience in epithelial cell biology, molecular biology and design and interpretation of translational animal studies.

Clinical Advisor
Jason Spector, M.D.
The respected plastic surgeon, clinical trial expert, and inventor
Clinician-Scientist at Weill Cornell Medical College and NIH funded researcher.

NOVYX TECHNOLOGIES

The Problem

Each year in the US over 6 million people suffer from chronic non-healing wounds that frequently enter a state of pathological inflammation, giving rise to severe chronic ulcers that, in the most extreme cases, can lead to amputation. Chronic wounds thus result in a diminished quality of life and prolonged hospital stays for patients, as well as increased massive costs and burdens for our healthcare system. In fact, over $30 Billion is spent on chronic wound care, annually.

The Doctor is limited in treatment options as the current treatment methods are only partially effective and expensive. For years research has been carried out to develop novel therapeutic approaches to stimulate healing of chronic wounds and reduce wound related complications.

Novyx Technologies has developed a material that stimulates such regeneration.



The Solution

Our company will introduce a regenerative wound dressing that reduces inflammation, increases the rate of healing, and ultimately enhances tissue regeneration following traumatic injury. This innovative wound dressing is adherent, flexible, and transparent to allow continuous monitoring of healing throughout treatment. Animal studies show that when this material is placed on a skin wound, it is absorbed naturally over a short time while simultaneously stimulating tissue growth and healing.

This wound dressing is easy to apply, less invasive than some current treatments, and is currently produced in our lab for less than $1. The production is fully scalable to large quantities and can be easily packaged and distributed in a similar fashion to a bandage.

Company Summary

Novyx Technologies is developing a regenerative wound dressing for skin wounds that prevents chronic inflammation and heals 3-5 times faster than the current treatment.

The Market

The annual US market size is currently $17 billion and expected to grow to $20 billion by 2021. This market includes the management and advanced care of chronic wounds caused by disease and trauma. A $100 million opportunity also lies in the veterinary care market.

Stage of Development

The technology has been developed by Novyx Technologies' founders and the provisional patents have been filed by Cornell University. The company has an option to license the technology from the University. The device is based on silk derived material. Silk has been shown to regenerate damaged tissue in multiple organs and has recently been FDA approved. Our company is applying this proven silk-based technology for skin regeneration. Initial animal studies show healing rates 3-5 times faster than untreated injuries.



Financial Highlights

Novyx Technologies is seeking $250K in seed funding to develop the initial product prototype and will need an additional $1 million to conduct animal studies and finalize preclinical studies. Additionally, we expect to license the product in 2019 to a veterinary company to help fund human trails.

Technology development costs will be covered through 2017 by $1k in awarded grants. From 2020 – 2021, Novyx Technologies expects to develop and carry out human trials. The trials will cost less than $5M due to low product manufacturing cost, straightforward medical procedure, and minimal human subject requirements. After Phase IIA FDA trials in 2021, we will pursue a partnership, license, or sale of the technology.